Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

IOVA

Hisse Senetlerindeki Sıralama #2895
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Hisse Fiyatı
$14.13
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$6.40B
Değişim (1 gün)
3.74%
Değişim (1 yıl)
509.05%
Ülke
US
Ticaret Iovance Biotherapeutics, Inc. (IOVA)

Kategori

Healthcare
Iovance Biotherapeutics, Inc. (IOVA) için temettü geçmişi
Iovance Biotherapeutics, Inc. (hisse sembolü: IOVA) toplam 0 temettü ödemesi yaptı.
Tüm temettülerin toplamı (hisse bölünmeleriyle ayarlanmış): 0.00
Temettü verimi (TTM): 0
Iovance Biotherapeutics, Inc. (IOVA) için 2026 ile 2026 arasındaki temettü ödemeleri
Yıllık temettü ödemeleri
Yıl Temettü (hisse bölünmesiyle ayarlanmış) Değiştir
Sağlanan tarihler için yeterli veri yok.
Tüm temettü ödemelerinin listesi
Yıl Temettü Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için temettü ödemeleri
Şirket Temettü ödemesi sayısı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL